Risk of Bias in Systematic Reviews with Cost and Cost-Effectiveness Outcomes

ISPOR Europe 2019
4 November 2019

Discussion Leaders

- **Salah Ghabri, PhD**, French National Authority for Health (HAS), Saint-Denis La Plaine, France
- **Lena Mandrik, PhD**, the University of Sheffield, Sheffield, England, UK
- **Hans Severens, PhD**, Erasmus University Rotterdam, Rotterdam, Netherlands
- **Torbjørn Wisløff, PhD**, The Arctic University of Norway, Tromsø, Norway
Task Force Members

- J.L. (Hans) Severens, PhD, Professor of Evaluation in Health Care, Dean, Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands (co-chair)
- Jeremy D Goldhaber-Fiebert, PhD, Associate Professor of Medicine, Core Faculty Member, Centers for Health Policy and Primary Care and Outcomes Research (CHP/PCOR), Stanford University, Stanford, CA, USA (co-chair)
- Olena (Lena) Mandrik, PhD, Research fellow, the University of Sheffield, Sheffield, England, UK (co-chair)
- Ariel Bardach, MD, PhD, Researcher, Health Technology Assessment (HTA) and Health Economic Evaluations Department, Institute for Clinical Effectiveness and Health Policy (IECS), Center for Epidemiology and Public Health Research (CIESP CONICET) and the Argentinean Cochrane Collaboration Center, Buenos Aires, Argentina
- Salah Ghabri, PhD, Health Economist/Project Coordinator, Haute Autorité de Santé (HAS), Saint Denis La Plaine, France
- Candyce Hamel, PhD, Senior Clinical Research Associate, Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, Canada
- Cristina Masseria, PhD, Methods and Capability Lead, Patient & Health Impact (PHI), Pfizer, New York, NY, USA
- Tim Mathes, PhD, Research Associate, Institute for Research in Operative Medicine (IFOM), Witten / Herdecke University, Cologne, Germany
- Luke Vale, PhD, Health Foundation Chair in Health Economics, and Deputy Director, Institute of Health & Society, Newcastle University and Chairman, Joint Economic Methods Group, Cochrane and Campbell Collaborations, Newcastle, England, UK
- Torbjorn Wisloff, PhD, Associate Professor, Department of Health Management and Health Economics, Institute of Health and Society (Helsam), University of Oslo, Oslo, Norway

Guidance on cost and cost-effectiveness evidence

Guidances on evaluation or reporting of original cost or cost-effectiveness studies
- CHEERS
- CHEC
- Drummond et al.
- Jefferson et al.

Guidances on preparing the reviews of evidence
- Cochrane
- Centre for Reviews and Dissemination at York
- PRISMA
- Mathes et al.

Guidances on evaluating the reviews of evidence
- AMSTAR
- OQAQ
- Jefferson et al.
What are we doing?

- The task force’s goal is to provide recommendations on reporting and evaluating the risk of bias of systematic reviews with cost or cost-effectiveness outcomes and various objectives:
  - Variability in outcomes
  - Quality of evidence or methods
  - Research gaps estimation
  - Mixed (clinical & economic reviews)

Objectives of the workshop

- To inform the ISPOR-membership on the latest developments and recommendations of the TF
- To raise the disputable points in the recommendations of the TF and receive a feedback from the ISPOR-membership
Outline of the workshop

1. Planning the review and literature search; Lena Mandrik
2. Literature selection and validation; Torbjørn Wisløff
3. Literature extraction and synthesis; Hans Severens
4. Presentation and reporting; Salah Ghabri
Planning the review (1): the protocol

**Includes:** (a) pre-established methods  (b) reported deviations

**Goals:**
- Reporting bias
- Transparency

**Potential concerns:**
- False statements on protocol availability
- Significant unreported deviations
- Difficult to compare the differences

**Possible solutions:**
- High confidence: publicly available (ex. publication, PROSPERO)
- Moderate confidence: registration and peer-review process (ex. **IRB approval**)

Planning the review (2): the aims and objectives

Potential concerns:
- PICO is not applicable
- Some components are missing
- Obligatory elements depends on the reviews objectives

Possible solutions:

<table>
<thead>
<tr>
<th>Obligatory elements</th>
<th>Advised elements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td>Intervention(s)</td>
</tr>
<tr>
<td>Outcome(s)</td>
<td>Comparator(s)</td>
</tr>
<tr>
<td>Study design</td>
<td>Timeframe</td>
</tr>
<tr>
<td></td>
<td>Stakeholder</td>
</tr>
</tbody>
</table>

Search in systematic reviews (1)

**Should be:** targeted, sound, complete, and reproducible

**Goal:** Retrieve all (most) articles relevant to each of the objectives

Transparency

**Potential concerns:**
- Time and resources available
- Missed publications
- Inconsistencies /low fit to objectives

**Potential solutions:**
- Involve information specialist or peer-review the search strategy
- Minimise inconsistencies and risk of bias if reusing the searches
- Justify if only 1-2 databases are searched
- Use objective-specific choice of databases and search-terms on either outcome:
  - Reviews with non-Global focus
  - Mixed reviews with clinical outcomes
Search in systematic reviews (2)

Supplementary searching:
- Bibliography review (snowballing approach)
- Experts’ opinion
- Grey literature

Useful resources:
PRESS guideline (McGowan, 2015): peer-review electronic search strategies
Search strategies:
Cochrane section 20 (Box 20.3.d, Box 20.3.e, Box 20.3.f);
Wood at el. (2017), doi: 10.1017/S0266462316000660

Search in systematic reviews (3): how grey is grey literature?

The main grey literature sources:
- HTA reports (CRD York, BRISA, the WHO, etc)
- Theses/dissertations (EBSCO open Dissertations, ProQuest Dissertations & Theses)

The concerns: Conference abstracts

Pros:
- Missed information
- Publication bias

Cons:
- Insufficient reporting
- Quality/consistency
Poll: Should conference abstracts be recommended as a source of grey literature for systematic reviews of costs or cost-effectiveness outcomes?

Final remark

- The methodological approach to searching is similar to clinical reviews
- Important differences are in objectives/ search terms and recommendations for grey literature
- The most challenging design is of the reviews reporting both effects and cost
Selection of evidence (1)

• Includes: Screening of titles, abstracts and full-texts
• Goals:
  – Transparency
  – Include all relevant studies
• Trade-off:
  – Time and resources available
• Potential problems:
  – Including studies that shouldn’t be included
  – Excluding studies that should be included
• Possible solutions:
  – Sensitivity analysis including excluded studies
Selection of evidence (2) – possible restrictions

• Publication date
  – Advantage: may increase generalizability if things have changed

• Country / region
  – Limits generalizability
  – Increases internal validity if the scope of the review is local

• Language
  – May bias outcomes

Validation / assessment (1)

• Evaluate study validity, generalisability and transferability

• Describe methods, assumptions, models and potential biases

• Provide a qualitative description and critique of the evidence base

• Differentiate between piggy-back and model-based economic evaluations
Validation / assessment (2)

- Useful tools:
  - BMJ checklist (Drummond 1996)
  - CHEC list (Evers 2005)
  - Philips checklist (Philips 2004, 2006)
  - CHEERS (Husereau 2013)
  - ECOBIAS (Adarkwah 2015)
  - Second panel on cost-effectiveness (Sanders 2016)
Assessment of methodological quality

- Validity
- Generalizability and transferability

A standard check-list should be chosen and justified for reporting of methodological reviews, cost effectiveness or costing studies.

- British Medical Journal Checklist f (Drummond 1996)
- CHEC list (Evers 2005)
- CHEERs (Husereau 2013)
- Second Panel on Cost-Effectiveness checklist (Sanders, 2016)
- ECOBIAS (Adarkwah et al, 2015)

At least two reviewers should assess the quality of studies independently.
Assessing risk of bias in original evidence

- The study design (partial vs full EE, trial-based (piggyback EE) or model-based).
- Type and quality of the underlying effectiveness data (e.g. trial data, observational data, meta-analysis).
- Non-methodological aspects (authors, year of publication, country/jurisdiction, type of condition, type of intervention, funding, etc.)
- Other methodological aspects of the study (objective, perspective, scoping, comparators, health effects, sources of cost data, inclusion of indirect costs, time horizon, utilities, discount rate, incremental analysis, sensitivity analysis, discussion/recommendations, generalizability)

Homogeneity / heterogeneity (1)

- Guiding questions (e.g., check boxes) to assess homogeneity:
  - patients comparable
  - interventions comparable
  - study designs/modelling comparable
  - country/jurisdiction
  - Etc
  - Etc
Synthesis of data

- Possible approaches:
  - (structured) narrative synthesis
  - graphical synthesis (e.g., cost-effectiveness diagram, permutation matrix)
  - quantitative synthesis/meta-analysis.

- There is no best way to synthesize economic evidence.

- The “right” approach depends on the degree of context/setting, clinical, and methodological heterogeneity in the studies:
  - More heterogeneous → narrative synthesis/comparison more appropriate
  - More homogeneous → quantitative methods appropriate that treat numeric estimates from each study as directly comparable

---

Synthesis

- Costs:
  - same currency
  - expressed in the same year
  - inflation adjusted
  - report original data (!)

- Separate synthesis in subsections (either narrative or quantitative):
  - modelling and piggyback studies
  - probabilistic and deterministic results
  - sensitivity analysis
Homogeneity / heterogeneity (2)

- Heterogeneity will imply that pooling such results is not appropriate.

- Only studies considered sufficiently homogeneous regarding contexts, settings, jurisdiction, administrative areas should be synthesized together.

Narrow or broad SR?
- Single/main synthesis is only applicable for narrowly focused SRs.
- SRs with a broad scope, applicable to many jurisdictions:
  - report the results for homogeneous subgroups
  - consciously selected, ideally based on predefined criteria.
How Economic outcomes should be presented (1)?

- Economic outcomes should be reported in **summary table(s)** → BOX 1
  - **A minimum of outcomes** should be presented
    - **SRs of CEA**
      - Outcomes of interest (e.g. total costs, life years, quality adjusted life years (QALYs)) should be reported for each included study.
    - **SRs of costs**
      - type of costs and costs valuation (volumes and prices separately) should be reported for each included study. Cost and health outcomes should be presented separately for each strategy within each study.
How Economic outcomes should be presented (2)?

**BOX 1: Example of summary table**

1. Countries
2. Population of analysis
3. Time horizon, perspective
4. Adjustment of inflation, Discount rate
5. Interventions compared
6. Method(s) for valuation of economic outcomes
   (a) Direct cost(s) (according to the horizon of interest)
   (b) Indirect costs (ex. productivity loss)
7. Method(s) for valuation of effectiveness outcomes including source, type of source, estimates, duration
8. Compliance/adherence with treatment
9. Decision analytic modeling or approach to calculation of economic outcomes
10. ICER and health outcomes (e.g. gained life years, number of death avoided, QALY)
11. Uncertainty (e.g. parametric and probabilistic uncertainty)
12. Heterogeneity (e.g. sub-populations analysis)
13. Conflicts of interest and sources of funding
14. Ethical and/or equity consideration
15. Software

How reporting of outcomes should be done?

- **A compromise** of reporting should be found between both reported outcomes in **summary tables** and their **narrative description** in small paragraphs
  - Page limitations → appendices/supplementary material
- **Extended reporting** is useful for specific studies types:
  - **complex economic decision models**:
    - model type and characteristics
    - model validation
    - most influential parameters affecting uncertainty
How assessment of potential SR-bias should be reported?

• The authors of SR should assess the impact of any potential bias related to findings of the conducted review:
  • conflict of interests
  • study funding and
  • potential factors explaining differences between studies

• The authors of SR should provide an explanation for any heterogeneity observed in the results of the review
**Poll: Should authors of cost and cost-effectiveness reviews assess transferability of the included studies to the context of a review?**

**Objectives of the workshop**

- To inform the ISPOR-membership on the latest developments and recommendations of the TF
- To raise the disputable points in the recommendations of the TF and receive a feedback from the ISPOR-membership
  - Abstract as grey literature?
  - Duplicated selection process?
  - Meta-analyses and pooling of data?
  - Assessment of publication bias?
  - Transferability to the context of a review
How to JOIN our Task Force Review Group

• Go to the Website
  – Member Groups
  – Task Forces
  – Click on Join a Review Group
  – Expected review March 2020

Slides are available on the ISPOR Europe 2019 webpage under program.
Open-ended questions for discussion

Is artificial intelligence tested enough for references screening to be included in the task force report?

Should recommendations on search in social networks be included in the task force report?
Risk of Bias in Systematic Reviews with Cost and Cost-Effectiveness Outcomes

ISPOR Europe 2019
4 November 2019